Biggest gainers and losers for May 11-15, 2026

Endpoints NewsAmgen stands by rare disease drug Tavneos amid Japan liver toxicity report

Endpoints NewsFDA's unreleased Covid vaccine deaths report is published by lawmaker

10x Genomics NewsThe 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call - Yahoo Finance

BioWorldMoney raised by biopharma

BioWorldBiopharma money raised: Jan. 1-May 15, 2026

BioPharma DiveFDA approves AstraZeneca’s new kind of hypertension drug

BioWorldAuthorities work to quickly sequence Ebola species in latest outbreak

BioPharma DiveMerck ADC, licensed from China, hits mark in first big global trial

Boston ScientificBoston Scientific buys $1.5B stake in TAVR developer MiRus - MedTech Dive

Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targets

FierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal

FierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger